EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Proteomic discoveries in hypermobile Ehlers–Danlos syndrome reveal insights into disease pathophysiology

Molly Griggs, Victoria Daylor, Taylor Petrucci iD, Amy Weintraub iD, Matthew Huff, Sofia Willey, Kathryn Byerly, Brian Loizzi, Jordan Morningstar iD, Lauren Elizabeth Ball iD, Jennifer R Bethard, Richard Drake und 9 weitere

ImmunoHorizons · 17.09.2025 · 9 (10)

DOI: 10.1093/immhor/vlaf044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoHorizons, online erschienen am 17.09.2025. Verfasst von Molly Griggs und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, United States. Hauptthemen laut MEDLINE: Ehlers-Danlos Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypermobile Ehlers–Danlos Syndrome (hEDS) is a poorly understood connective tissue disorder that lacks molecular diagnostic markers. This study aimed to identify proteomic signatures associated with hEDS to define underlying pathophysiology and to inform objective diagnostic strategies with therapeutic potential. An unbiased mass spectrometry–based proteomic analysis of serum from female hEDS patients (n = 29) and matched controls (n = 29) was conducted. Differentially abundant proteins were analyzed through pathway enrichment and gene ontology pipelines. Prioritized candidate biomarker proteins were verified in expanded patient and control cohorts via ELISA. Cytokine array profiling was conducted to assess immune signaling patterns. Proteomic analysis revealed 35 differentially expressed proteins in hEDS, with 43% involved in the complement cascade and 80% linked to immune, coagulation, or inflammatory pathways. Pathway analyses confirmed enrichment in complement activation, coagulation, and stress responses. ELISA validation showed significant reductions in C1QA, C3, C8A, C8B, and C9 in hEDS patients, consistent across age and sex. Cytokine profiling revealed alterations in nodal immune cell mediators in hEDS patients, supporting a model of dysregulated inflammatory response. Our findings indicate a systemic immune dysregulation, particularly involving the complement system and profibrotic cytokines, as a common feature in hEDS pathophysiology. These findings challenge the traditional view of hEDS as solely a connective tissue disorder and support a revised paradigm that includes innate immune dysfunction. This immune involvement may contribute to disease pathophysiology and inform the development of biologically based diagnostic tools, enabling earlier diagnosis and guiding future therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ehlers-Danlos SyndromeHumansFemaleProteomicsAdultBiomarkersCytokinesComplement ActivationYoung AdultComplement System ProteinsMiddle AgedAdolescentCase-Control Studies

Stichwörter der Autor:innen

biomarkerscomplementconnective tissue diseasecytokinesproteomics

Substanzen

BiomarkersCytokinesComplement System Proteins

Autor:innen und Institutionen

  • Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, United States.
  • Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, United States.
  • Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, United States.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, Charleston, SC, United States.
  • Department of Orthopaedics, Medical University of South Carolina, Charleston, SC, United States.
  • Department of Health Sciences and Research, Medical University of South Carolina, Charleston, SC, United States.

ORCID-Profile: Taylor Petrucci, Amy Weintraub, Jordan Morningstar, Lauren Elizabeth Ball, Cortney Gensemer

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NCRR NIH HHS
  • Fullerton Foundation
  • Maltz Foundation
  • Ehlers–Danlos Society

Zitieren

APA

Griggs, M., Daylor, V., Petrucci, T., Weintraub, A., Huff, M., Willey, S., Byerly, K., Loizzi, B., Morningstar, J., Ball, L. E., Bethard, J. R., Drake, R., Sharma, A., Eichinger, J. K., Nichols, M., Kautz, S., Shapiro, S., Maitland, A., Patel, S., …, & Gensemer, C. (2025). Proteomic discoveries in hypermobile Ehlers–Danlos syndrome reveal insights into disease pathophysiology. ImmunoHorizons, 9(10). https://doi.org/10.1093/immhor/vlaf044

Vancouver

Griggs M, Daylor V, Petrucci T, Weintraub A, Huff M, Willey S, et al. Proteomic discoveries in hypermobile Ehlers–Danlos syndrome reveal insights into disease pathophysiology. ImmunoHorizons. 2025;9(10). doi:10.1093/immhor/vlaf044

BibTeX
@article{Griggs2025,
  author = {Griggs, Molly and Daylor, Victoria and Petrucci, Taylor and Weintraub, Amy and Huff, Matthew and Willey, Sofia and Byerly, Kathryn and Loizzi, Brian and Morningstar, Jordan and Ball, Lauren Elizabeth and Bethard, Jennifer R and Drake, Richard and Sharma, Amol and Eichinger, Josef K and Nichols, Michelle and Kautz, Steven and Shapiro, Steven and Maitland, Anne and Patel, Sunil and Norris, Russell A and Gensemer, Cortney},
  title = {Proteomic discoveries in hypermobile Ehlers–Danlos syndrome reveal insights into disease pathophysiology},
  journal = {ImmunoHorizons},
  year = {2025},
  volume = {9},
  number = {10},
  doi = {10.1093/immhor/vlaf044}
}
Kostenlos starten →